- ImmunityBio (IBRX, Financial) to present new clinical findings for ANKTIVA® at AUA 2025 in Las Vegas.
- Key oral presentations will focus on long-term efficacy data from the QUILT-3.032 trial.
- The company has submitted a Supplemental Biologics License Application for ANKTIVA.
ImmunityBio, Inc. (IBRX), a front-runner in immunotherapy, is set to unveil pivotal clinical findings surrounding its innovative candidate ANKTIVA® at the American Urological Association (AUA) Annual Meeting 2025. This significant event, held from April 26-29 at The Venetian Convention & Expo Center in Las Vegas, will spotlight the latest updates from the QUILT-3.032 trial, emphasizing the durable complete responses in patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS).
Key presentations at the conference will include an in-depth analysis of long-term efficacy data for ANKTIVA in combination with BCG, showcasing resilience against BCG-unresponsive NMIBC CIS. Notably, ImmunityBio has filed a Supplemental Biologics License Application aimed at extending the use of ANKTIVA for broader patient access, alongside an application for its Expanded Access Authorization as a BioShield for those undergoing chemotherapy, radiation, and immunotherapy.
This initiative underscores ImmunityBio's commitment to addressing the BCG shortage and expanding the horizons of cancer treatment. Dr. Patrick Soon-Shiong, Founder and Executive Chairman of the company, is poised to headline multiple sessions, discussing innovations in urological cancer therapy and detailing the potential of ANKTIVA to establish new standards in the fight against urological malignancies.
